SCHADE CHRISTIAN S 4

What Happened

• Christian S. Schade, a director of Integra LifeSciences Holdings Corp. (IART), was granted 17,700 restricted stock units (RSUs) on May 7, 2026. The Form 4 shows an acquisition price of $0 (typical for awards); the RSUs are a derivative award representing a right to receive one share of IART common stock per RSU upon vesting.

Key Details

• Transaction date: May 7, 2026 (reported on Form 4 filed May 11, 2026).
• Grant: 17,700 RSUs; acquisition price reported as $0 (derivative award).
• Vesting: RSUs vest in full on the one-year anniversary of the grant (May 7, 2027) (Footnote F2).
• Delivery/deferral: The reporting person elected to defer receipt; vested shares will be delivered in one lump sum in the calendar year after the reporting person's board service ends (unless a later year was elected) (Footnote F2).
• Plan: Issued under the Integra Fifth Amended and Restated 2003 Equity Incentive Plan (Footnote F1).
• Shares owned after transaction: Not specified in the provided filing.
• Filing timeliness: Transaction dated May 7, filed May 11 (4 days later). Insider Form 4s are generally required within 2 business days, so this filing appears later than the standard reporting window.

Context

• RSUs are a compensation award (code A) and are not an open-market purchase or sale; they represent contingent rights to future shares and do not necessarily indicate immediate buying or selling sentiment. Because the reporting person elected to defer delivery, the actual share receipt is tied to future vesting and post-service timing, not an immediate transfer of shares.